Gene

CTAG1B

cancer/testis antigen 1B

Curated evidence

Clinical evidence (2)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
CTAG1B Expression1
Letetresgene Autoleucel	Myxoid Liposarcoma	Predictive	B	Supports Sensitivity Response	3	accepted	EID12573 In the phase II trial (NCT02992743) of letetresgene autoleucel (lete-cel) in human leukocyte antigen ((HLA)-A02:01–, HLA-A02:05–, and/or HLA-A*02:06–positive), NY-ESO-1 (CTAG1B)-expressing advanced … (full text at CIViC) PMID 39836945 · D'Angelo et al., 2025 · Open in CIViC	civic
CTAG1B Overexpression1
Letetresgene Autoleucel	Multiple Myeloma	Predictive	B	Supports Sensitivity Response	3	accepted	EID2940 Clinical responses to NY-ESO-1/LAGE-1 TCR-engineered T-cells were observed in 16 of 20 patients (80%) with advanced multiple myeloma expressing NY-ESO-1 and/or LAGE-1 in this Phase 1/2a trial showing …

Cohorts

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

Data not yet available

No cohort frequency recorded for this gene.

Literature

25 per page, newest first.

pubmedPublishedShowing 1–2 of 2 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.